Overview

Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease

Status:
Completed
Trial end date:
2020-07-14
Target enrollment:
Participant gender:
Summary
This study is to assess the effect of 48 weeks administration of Renamezin capsule on prevention of sarcopenia in pre-dialysis patients with chronic kidney disease.
Phase:
Phase 4
Details
Lead Sponsor:
Gumi Cha Medical Center